Donate

ASCO Releases A Statement of Principles Balancing Patient Access to Opioids with Curbing Drug Abuse

The American Association of Clinical Oncology (ASCO) released a very important new policy statement that details their position surrounding the prescribing of  opioids to cancer patients. This issue has taken the forefront of controversy as our society increasingly becomes concerned about the overuse of prescription opioids, sometimes leaving out the very specific needs of cancer [...]

Three Videos Of Interest To The Prostate Cancer Community

Recently our long time partner, Patient Power (https://www.patientpower.info) has produced a number of videos that are of significant interest to all members of the prostate cancer community. Darryl Mitteldorf, Executive Director of Malecare talks about Malecare and what it does for men with cancer at: https://malecare.org Darryl Mitteldorf, founder of the National LGBT Cancer Project [...]

By |2021-02-17T10:42:37-05:00June 21st, 2016|Advanced Prostate Cancer, ASCO, Malecare, Uncategorized|0 Comments

REVIEW – Statins Boost Abiraterone (Zytiga) Activity in Prostate Cancer

Another piece of information from the recent ASCO GU conference in San Francisco Researchers have found that adding statin drugs may prolong the sensitivity of abiraterone acetate (Zytiga) in men with castration-resistant prostate cancer (CRPC) To assess the effect of statins on abiraterone therapy, Dr Harshman, of the Lank Center for Genitourinary Oncology at Dana-Farber [...]

Repeating Treatment with Radium-223 (Xofigo) is Safe and Effective

Radium-223 (Xofigo) is a drug for men with castrate resistant metastatic prostate cancer (mCRCP) who have multiple bone metastases. Radium-223 selectively targets bone metastases by mimicking calcium, which is attracted to the bone, especially to the fast growing areas of the tumor in the bone. It emits an alpha-emitting dose of radiation, which is mostly contained [...]

For Men with Prostate Cancer Does Being Married or Partnered Extend Your Life, A Myth Shattered

I just returned, along with Malecare’s Executive Director Darryl Mitteldorf and Dr. Wendy Lebowitz, from the ASCO Genitourinary Cancers Symposium in San Francisco. The three of us often attend this meeting, but this one had a new and very special item, a research poster (abstract no. 253) that was presented by Malecare and Mitteldorf. The [...]

Are You Having Trouble Getting Early Access To Chemotherapy?

During last year’s American Society of Clinical Oncologists (ASCO) Annual Meeting, data was released from the STAMPEDE trial which should change clinical practice around the world. The trial results showed that newly diagnosed men with very aggressive prostate cancer that was still hormone therapy naive (no ADT) would have a very significant survival advantage by [...]

Describing My Experience Being Diagnosed With A Fifth Cancer – A Video To Watch

I attend the American Society of Clinical Oncology (ASCO) meeting in Chicago in May.  As usual, it was exciting and it provides me with a fantastic opportunity to catch up with the current research in advanced prostate cancer.  It also gives me an opportunity to meet with and have private conversations with some of the [...]

A Step Towards Understanding How To Get A Fair Value For The Dollars Spent For Advanced Prostate Cancer Treatment

In the treatment of prostate cancer the first very expensive drug we had that was FDA approved was Provenge, with an initial cost of $93,000 for a one-month’s treatment protocol. Today, the cost is in excess of $106,000. According to the phase III clinical trial result Provenge extends life by a median of 4.1 months, [...]

It Maybe Time To Change The Dosing Schedule Of Zoledronic Acid To Every 12 Weeks

In a presentation at the ASCO Annual Meeting,  Dr. Andrew Himelstein, MD, FACP of the Helen F. Graham Cancer Center & Research Institute, presented the results of a trial evaluating Zoledronic Acid (Zometa) at a dosing schedule of every 12 weeks as opposed to the current standard of care of every 4 weeks. The trial included [...]

Combination Chemotherapy Treatments Maybe More Effective Than Each Drug In Sequence

According to a news release from MD Anderson they have recently completed a study that shows that combining two separate chemotherapy agents is more effective than sequencing them one after another. The current standard of care for the cytotoxic chemotherapy agents used to treat prostate cancer is to treat men with advanced metastatic castration-resistant prostate [...]

Go to Top